{"id":"https://openalex.org/W2565294276","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e18571","title":"The potential of the human CD38-specific antibody daratumumab to improve the antimyeloma effect of novel multidrug therapies including patients refractory to lenalidomide or bortezomib.","display_name":"The potential of the human CD38-specific antibody daratumumab to improve the antimyeloma effect of novel multidrug therapies including patients refractory to lenalidomide or bortezomib.","publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2565294276","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e18571","mag":"2565294276"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.e18571","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e18571","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.e18571","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080836916","display_name":"Tuna Mutis","orcid":"https://orcid.org/0000-0002-5557-7187","observed_orcids":["https://orcid.org/0000-0002-5557-7187"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Mutis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020011009","display_name":"Michel de Weers","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. de Weers","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079950416","display_name":"Michael S. van der Veer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. S. van der Veer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042793160","display_name":"Berris van Kessel","orcid":"https://orcid.org/0009-0009-9298-4820","observed_orcids":["https://orcid.org/0009-0009-9298-4820"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. v. Kessel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"J. M. Bakker","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. M. Bakker","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049251029","display_name":"Shulamiet H. Wittebol","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Wittebol","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039190287","display_name":"Paul W.H.I. Parren","orcid":"https://orcid.org/0000-0002-4365-3859","observed_orcids":["https://orcid.org/0000-0002-4365-3859"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. Parren","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5110098171","display_name":"Henk M. Lokhorst","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. M. Lokhorst","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"e18571","last_page":"e18571"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/daratumumab","display_name":"daratumumab","score":0.9639999866485596},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.984000027179718},{"id":"https://openalex.org/keywords/cd38","display_name":"CD38","score":0.8040000200271606},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9959999918937683},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7829999923706055},{"id":"https://openalex.org/keywords/refractory-multiple-myeloma","display_name":"refractory multiple myeloma","score":0.824999988079071},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.906000018119812},{"id":"https://openalex.org/keywords/complement-dependent-cytotoxicity","display_name":"complement-dependent cytotoxicity","score":0.9210000038146973},{"id":"https://openalex.org/keywords/multidrug-resistance","display_name":"multidrug resistance","score":0.33399999141693115}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8178234100341797},{"id":"https://openalex.org/C2781119759","wikidata":"https://www.wikidata.org/wiki/Q5222113","display_name":"Daratumumab","level":4,"score":0.7976628541946411},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.7259408831596375},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.7129722237586975},{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.6001723408699036},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.4698578119277954},{"id":"https://openalex.org/C2778684742","wikidata":"https://www.wikidata.org/wiki/Q2298283","display_name":"Melphalan","level":3,"score":0.46424755454063416},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.4611089825630188},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.42307227849960327},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3473557233810425},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.32780951261520386},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.29619479179382324},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2923166751861572},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.12319287657737732}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.e18571","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e18571","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.e18571","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2560042446","https://openalex.org/W2529222733","https://openalex.org/W2584309972","https://openalex.org/W1967198288","https://openalex.org/W2549442207","https://openalex.org/W2341176381","https://openalex.org/W2010232494","https://openalex.org/W1994013901","https://openalex.org/W2980265802","https://openalex.org/W2018962392"],"abstract_inverted_index":{"e18571":[0],"Background:":[1],"Multiple":[2],"myeloma":[3],"(MM)":[4],"represents":[5],"an":[6],"incurable":[7],"malignancy":[8],"of":[9,50,117,134,144,174,184,196,209,258,268],"antibody-producing":[10],"clonal":[11],"plasma":[12],"cells.":[13],"Over":[14],"the":[15,74,132,137,142,172,177,182,204,255],"past":[16],"decade":[17],"significant":[18],"progress":[19],"has":[20],"been":[21],"made":[22],"in":[23,90,120,194,254,272],"MM":[24,54,79,84,97,118,126,228,250,269],"treatment":[25,146,186,195,267],"using":[26],"novel":[27,83,240,260,275],"immunomodulating":[28],"agents":[29],"such":[30],"as":[31],"lenalidomide":[32],"(LEN)":[33],"and":[34,68,163,245],"bortezomib":[35],"(BORT).":[36],"Daratumumab":[37],"(DARA)":[38],"is":[39],"a":[40,47],"first-in-class":[41],"human":[42],"therapeutic":[43],"CD38-specific":[44],"antibody":[45],"with":[46,86,103,152,239,270,274],"broad":[48],"mechanism":[49],"action.":[51],"DARA":[52,102,135,148,175,226,236,271],"mediates":[53],"cell":[55,98,229,251],"death":[56],"primarily":[57],"via":[58],"ADCC":[59],"(antibody":[60],"dependent":[61,66],"cellular":[62],"cytotoxicity),":[63],"CDC":[64],"(complement":[65],"cytotoxicity)":[67],"apoptosis.":[69],"We":[70],"are":[71],"currently":[72],"exploring":[73],"possibility":[75],"to":[76,114,136,176,203,219,232],"further":[77],"improve":[78],"therapy":[80],"by":[81,100],"combining":[82,101],"therapeutics":[85],"DARA.":[87],"Our":[88,263],"initial":[89],"vitro":[91],"work":[92],"already":[93],"showed":[94,200],"significantly":[95,140,180],"improved":[96,193],"killing":[99,116,190,230,252],"LEN":[104],"treatment.":[105],"Methods:":[106],"In":[107,223],"ex":[108],"vivo":[109],"assays,":[110],"which":[111,199],"allow":[112],"us":[113],"address":[115],"cells":[119],"bone":[121],"marrow":[122],"aspirates":[123],"isolated":[124],"from":[125,214],"patients,":[127],"we":[128,169],"now":[129],"investigated":[130],"whether":[131],"addition":[133,173],"LEN+BORT":[138,145,178,185],"combination":[139,157,179,273],"exceeds":[141,181],"effectiveness":[143,183],"alone.":[147],"was":[149,191,237],"also":[150],"combined":[151,238],"two":[153],"recently":[154],"introduced":[155],"triple":[156,241],"therapies:":[158],"LEN,":[159],"BORT,":[160],"dexamethasone":[161],"(RVD)":[162],"melphalan,":[164],"prednisone,":[165],"BORT":[166,220],"(MPV).":[167],"Results:":[168],"demonstrate":[170],"that":[171,266],"alone":[187],"(P<0.001).":[188],"Strikingly,":[189],"most":[192],"patient":[197],"samples":[198,211,225],"poor":[201],"responses":[202],"LEN-BORT":[205],"combination.":[206],"Notably,":[207],"5":[208],"these":[210,224,259],"were":[212,217],"derived":[213],"patients":[215],"who":[216],"refractory":[218],"and/or":[221],"LEN.":[222],"increased":[227],"up":[231],"50%.":[233],"Furthemore,":[234],"when":[235],"agent":[242],"regimens":[243],"RVD":[244],"MPV,":[246],"it":[247],"almost":[248],"doubled":[249],"especially":[253],"low-dose":[256],"range":[257],"cocktails.":[261],"Conclusions:":[262],"results":[264],"illustrate":[265],"multidrug":[276],"therapies":[277],"bears":[278],"great":[279],"promise.":[280]},"counts_by_year":[{"year":2015,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-01-06T00:00:00"}